In order to shed light on the mechanism(s) of interaction between the pharmaceutical IgG and oxaliplatin, we evaluated the levels of ERCC1 and p-ERK1/2, two proteins that might be involved in the cell toxicity of oxaliplatin.10–15 After incubation of colon cancer cells with 5 mg/mL PRIVIGEN®, 6.25 μM oxaliplatin or the combinatorial therapy, we observed that both IgG and oxaliplatin had no effect on the accumulation of ERCC1 (Supplementary Fig. 4). The gene discussed is MAPK3; the disease is malignant colon neoplasm.